Scholar Rock Holding (SRRK) Common Equity (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Common Equity of $276.0 million for Q1 2026, down 11.63% year-over-year from $312.3 million in Q1 2025, and up 12.43% quarter-over-quarter from $245.5 million in Q4 2025.
Scholar Rock Holding (SRRK) Common Equity (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Common Equity history runs 10 years deep, the most recent figure standing at $276.0 million for Q1 2026.
- In Q1 2026, Common Equity fell 11.63% year-over-year to $276.0 million; the TTM figure through Mar 2026 stood at $276.0 million (down 11.63% YoY), while the FY2025 annual figure was $245.5 million, down 33.41% from the prior year.
- Common Equity for Q1 2026 stood at $276.0 million, up from $245.5 million in the prior quarter.
- The five-year high for Common Equity was $368.6 million in Q4 2024, with the low at $79.2 million in Q3 2024.
- The 5-year median for Common Equity is $233.3 million (2025), against an average of $232.6 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity sank 52.77% in 2024, then surged 209.35% in 2025.
- Scholar Rock Holding's Common Equity stood at $260.2 million in 2022, then slipped by 13.46% to $225.2 million in 2023, then jumped by 63.68% to $368.6 million in 2024, then tumbled by 33.41% to $245.5 million in 2025, then increased by 12.43% to $276.0 million in 2026.
- Business Quant data shows SRRK's Common Equity at $276.0 million in Q1 2026, $245.5 million in Q4 2025, and $245.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - | 253.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 253.78 Mn |
| Mar 31, 2026 | 276.01 Mn |
| Dec 31, 2025 | 245.49 Mn |
| Sep 30, 2025 | 245.00 Mn |
| Jun 30, 2025 | 233.29 Mn |
| Mar 31, 2025 | 312.33 Mn |
| Dec 31, 2024 | 368.63 Mn |
| Sep 30, 2024 | 79.20 Mn |
| Jun 30, 2024 | 133.62 Mn |
| Mar 31, 2024 | 182.77 Mn |
| Dec 31, 2023 | 225.22 Mn |
| Sep 30, 2023 | 167.67 Mn |
| Jun 30, 2023 | 202.50 Mn |
| Mar 31, 2023 | 228.65 Mn |
| Dec 31, 2022 | 260.24 Mn |
| Sep 30, 2022 | 293.27 Mn |
| Jun 30, 2022 | 329.51 Mn |
| Mar 31, 2022 | 171.32 Mn |
| Dec 31, 2021 | 172.07 Mn |
| Sep 30, 2021 | 187.26 Mn |